Bisphosphonate use has increased in veterinary medicine over the last decade. During this time, bisphosphonate related osteonecrosis of the jaws (BRONJ) in human patients has been identified. Only recently was a dog model for BRONJ developed for human oral surgery and medicine. Veterinary patients treated with bisphosphonates may be at an increased risk for BRONJ. There has been little, to no, investigation of potential long term side-effects of bisphosphonate use in veterinary patients; potential sequelae are unknown. The history of bisphosphonates, their use, and BRONJ in veterinary patients are discussed.
Get full access to this article
View all access options for this article.
References
1.
RuggieroSL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development. J Oral Maxillofac Surg2009; 67 (5 Suppl):13–18.
2.
LoJCO'RyanFSGordonNP. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg2010; 68(2): 243–253.
3.
KnightRJReddyCRtshiladzeMA. Bisphosphonate-related osteonecrosis of the jaw: Tip of the iceberg. J Craniofac Surg2010; 21(1): 25–32.
4.
FanTM. The role of bisphosphonates in the management of patients that have cancer. Vet Clin North Am Small Anim Pract2007; 37(6): 1091–110; vi.
5.
FanTM. Intravenous aminobisphosphonates for managing complications of malignant osteolysis in companion animals. Top Companion Anim Med2009; 24(3): 151–156.
6.
SodekJMcKeeMD. Molecular and cellular biology of alveolar bone. Periodontol 20002000; 24:99–126.
7.
BosshardtDD. Are cementoblasts a subpopulation of osteoblasts or a unique phenotype?J Dent Res2005; 84(5): 390–406.
8.
BoyceBFXingL. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther2007; 9Suppl 1:S1.
9.
LandesbergREisigSFennoyI. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg2009; 67(5 Suppl): 27–34.
10.
MehrotraB. Bisphosphonates–role in cancer therapies. J Oral Maxillofac Surg2009;67 (5 Suppl): 19–26.
11.
BadranZKraehenmannMAGuicheuxJ. Bisphosphonates in periodontal treatment: A review. Oral Health Prev Dent2009; 7(1): 3–12.
12.
ShinodaHTakeyamaSSuzukiK. Pharmacological topics of bone metabolism: A novel bisphosphonate for the treatment of periodontitis. J Pharmacol Sci2008;106 (4): 555–558.
13.
RumbeihaWKFitzgeraldSDKrugerJM. Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs. Am J Vet Res2000; 61(1): 9–13.
14.
KadarERushJEWetmoreL. Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy. J Am Anim Hosp Assoc2004; 40(1): 75–81.
15.
WiseLMWaldmanSDKasraM. Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int2005;77(6):367–375.
16.
HostutlerRAChewDJJaegerJQ. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. J Vet Intern Med2005;19(1): 29–33.
17.
FanTMde LorimierLPCharneySC. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med2005;19(1): 74–80.
18.
de LorimierLPFanTM. Bone metabolic effects of single-dose zoledronate in healthy dogs. J Vet Intern Med2005; 19(6): 924–927.
19.
AshtonJAFareseJPMilnerRJ. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res2005; 66(5): 885–891.
20.
AgnelloKATrumbleTNChambersJN. Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis. Am J Vet Res2005; 66(9): 1487–1495.
21.
FarrellMLindsaySJohnsonV. Massive osteolysis in a dog resembling Gorham's disease in humans. Vet Comp Orthop Traumatol2011; 24(5): 389–397.
22.
MoreauMRiallandPPelletierJP. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther2011;13(3):R98.
23.
FanTMde LorimierLPO'Dell-AndersonK. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med2007; 21(3): 431–439.
24.
WypijJMFanTMFredricksonRL. In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats. J Vet Intern Med2008; 22(1):158–163.
25.
FanTMde LorimierLPGarrettLD. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis. J Vet Intern Med2008; 22(2):380–387.
26.
SpugniniEPVincenziBCarusoG. Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. J Small Anim Pract2009; 50(1):44–46.
27.
FanTMCharneySCde LorimierLP. Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med2009;23(1):152–160.
28.
BottcherPKrastelDHierholzerJ. Percutaneous cementoplasty in the palliative, multimodal treatment of primary bone tumors of the distal aspect of the radius in four dogs. Vet Surg2009; 38(7): 888–901.
29.
HafemanSLondonCElmslieR. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother2010; 59(3): 441–452.
30.
WhitneyJLBarrsVRWilkinsonMR. Use of bisphosphonates to treat severe idiopathic hypercalcaemia in a young Ragdoll cat. J Feline Med Surg2011;13(2):129–134.
31.
MohnKLJacksTMSchleimKD. Alendronate binds to tooth root surfaces and inhibits progression of feline tooth resorption: A pilot proof-of-concept study. J Vet Dent2009; 26(2): 74–81.
32.
GrubbT. What do we really know about the drugs we use to treat chronic pain?Top Companion Anim Med2010; 25(1): 10–19.
33.
De LucaALamuraLGalloM. Pharmacokinetic evaluation of zoledronic acid. Expert Opin Drug Metab Toxicol2011; 7: 911–918.
34.
CremersSPapapoulosS. Pharmacology of bisphosphonates. Bone2011; 49: 42–49.
35.
PorrasAGHollandSDGertzBJ. Pharmacokinetics of alendronate. Clin Pharmacokinet1999; 36: 315–328.
36.
LinJH. Bisphosphonates: A review of their pharmacokinetic properties. Bone1996; 18: 75–85.
37.
Martin-JimenezTDe LorimierLPFanTM. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs. J Vet Pharmacol Ther2007; 30: 492–495.
38.
TiptonDASeshulBADabbousMK. Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. J Periodontal Res2010; 1–9.
39.
KennelKADrakeMT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc2009; 84: 632–637.
40.
VestergaardP. Occurrence of Gastrointestinal Cancer in Users of Bisphosphonates and Other Antiresorptive Drugs Against Osteoporosis. Calcif Tissue Int2011; 89: 434–441.
41.
RozenbergSDuttonS. Bisphosphonates and oesophageal cancer risk: Where are we now?Maturitas2011; 68: 106–108.
42.
WysowskiDK. Oral bisphosphonates and oesophageal cancer. BMJ2010; 341: c4506.
43.
GreenJCzannerGReevesG. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ2010; 341: c4444.
44.
CardwellCRAbnetCCCantwellMM. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA2010; 304: 657–663.
45.
KennelKADrakeMT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc2009; 84: 632–637.
46.
KharazmiMSjoqvistKRizkM. Oral ulcer associated with alendronate: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2010; 110: e11–13.
47.
ReidIR. Osteonecrosis of the jaw: Who gets it, and why?Bone2009; 44: 4–10.
48.
SilvermanSLLandesbergR. Osteonecrosis of the jaw and the role of bisphosphonates: A critical review. Am J Med2009; 122(2 Suppl): S33–45.
49.
RuggieroS. Bisphosphonate-Related Osteonecrosis if the Jaws. Compendium of continuing education in dentistry (Jamesburg, N J: 1995) 2008; 29: 97–105.
50.
DodsonTB. Intravenous Bisphosphonate Therapy and Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg2009; 67(Suppl 1): 44–52.
51.
RuggieroSLDodsonTBAssaelLA. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg2009; 67(5 Suppl): 2–12.
52.
AllenMRBurrDB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data. J Oral Maxillofac Surg2009; 67(5 Suppl): 61–70.
53.
ChaturvediPPaiPSChaukarDA. Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: A word of caution for oral surgeons and oncologists. Eur J Surg Oncol2010; 36: 541–545.
54.
TruongSVChangLCBergerTG. Bisphosphonate-related osteonecrosis of the jaw presenting as a cutaneous dental sinus tract: A case report and review of the literature. J Am Acad Dermatol2010; 62: 672–676.
55.
MawardiHTreisterNRichardsonP. Sinus tracts–an early sign of bisphosphonate-associated osteonecrosis of the jaws?J Oral Maxillofac Surg2009; 67: 593–601.
56.
NaikNHRussoTA. Bisphosphonate-related osteonecrosis of the jaw: The role of actinomyces. Clin Infect Dis2009; 49: 1729–1732.
57.
AllenMR. Bisphosphonates and osteonecrosis of the jaw: Moving from the bedside to the bench. Cells tissues organs2009; 189(1–4): 289–294.
58.
AllenM.R.BurrD. B.. The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypothesis, So Few Data. J Oral Maxillofac Surg2009; 67(Suppl 1): 61–70.
59.
OttoSHafnerSMastG. Bisphosphonate-related osteonecrosis of the jaw: Is pH the missing part in the pathogenesis puzzle?J Oral Maxillofac Surg2010; 68: 1158–1161.
60.
GillSBValenciaMPSabinoML. Bisphosphonate-related osteonecrosis of the mandible and maxilla: Clinical and imaging features. J Comput Assist Tomogr2009; 33: 449–454.
61.
AssaelLA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: Clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg2009; 67(5 Suppl): 35–43.
62.
TreisterNSFriedlandBWooSB. Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2010; 109: 753–764.
63.
O'RyanFSKhourySLiaoW. Intravenous bisphosphonate-related osteonecrosis of the jaw: Bone scintigraphy as an early indicator. J Oral Maxillofac Surg2009; 67: 1363–1372.
64.
SingerSRMupparapuM. Plain film and CBCT findings in a case of bisphosphonate-related osteonecrosis of the jaw. Quintessence Int2009; 40: 163–165.
65.
BedogniABlandamuraSLokmicZ. Bisphosphonate-associated jawbone osteonecrosis: A correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2008; 105: 358–364.
66.
Abu-IdMHWarnkePHGottschalkJ. “Bis-phossy jaws” – high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg2008; 36: 95–103.
67.
ZakM. Bisphosphonates and the Dental Patient: Part 2. Compend Contin Educ Dent2007; 28: 510–516.
68.
MarxRESawatariYFortinM. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg2005; 63: 1567–1575.
69.
HarveyCE. Periodontal disease in dogs. Etiopathogenesis, prevalence, and significance. Vet Clin North Am Small Anim Pract1998; 28:1111–1128.
70.
HullPSSoamesJVDaviesRM. Periodontal disease in a Beagle dog colony. J Comp Pathol1974; 84: 143–150.
71.
RosenbergHMRehfeldCEEmmeringTE. A method for the epidemiologic assessment of periodontal health-disease state in a beagle hound colony. J Periodontol1966; 37: 208–213.
72.
IsogaiHIsogaiEOkamotoH. Epidemiological study on periodontal diseases and some other dental disorders in dogs. Nihon Juigaku Zasshi1989; 51: 1151–1162.
KortegaardHEEriksenTBaelumV. Periodontal disease in research beagle dogs–an epidemiological study. J Small Anim Pract2008; 49: 610–616.
75.
SorensenWPLoeHRamfjordSP. Periodontal disease in the beagle dog. A cross sectional clinical study. J Periodontal Res1980; 15: 380–389.
76.
HarveyCEShoferFSLasterL. Association of age and body weight with periodontal disease in North American dogs. J Vet Dent1994; 11: 94–105.
77.
VerstraeteFJKassPHTerpakCH. Diagnostic value of full-mouth radiography in dogs. Am J Vet Res1998; 59: 686–691.
78.
VerstraeteFJKassPHTerpakCH. Diagnostic value of full-mouth radiography in cats. Am J Vet Res1998; 59: 692–695.
79.
LommerMJVerstraeteFJ. Radiographic patterns of periodontitis in cats: 147 cases (1998–1999). J Am Vet Med Assoc2001; 218: 230–234.
80.
VahtsevanosKKyrgidisAVerrouE. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol2009; 27: 5356–5362.
81.
MarkoseGMackenzieFRCurrieWJ. Bisphosphonate osteonecrosis: A protocol for surgical management. Br J Oral Maxillofac Surg2009; 47: 294–297.
82.
LazaroviciTSYahalomRTaicherS. Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients. J Oral Maxillofac Surg2009; 67: 850–855.
83.
LodiGSardellaASalisA. Tooth extraction in patients taking intravenous bisphosphonates: A preventive protocol and case series. J Oral Maxillofac Surg2010; 68: 107–110.
84.
StubingerSDissmannJPPinhoNC. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation. Lasers Surg Med2009; 41: 26–30.
85.
StantonDCBalasanianE. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: Review of 33 surgical cases. J Oral Maxillofac Surg2009; 67: 943–950.
86.
RuganiPAchamSTruschneggA. Bisphosphonate-associated osteonecrosis of the jaws: Surgical treatment with ErCrYSGG-laser. Case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2010; 110: e1–6.
87.
EpsteinMSWicknickFWEpsteinJB. Management of bisphosphonate-associated osteonecrosis: Pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2010; 110: 593–596.
88.
RuggieroSLMehrotraB. Bisphosphonate-related osteonecrosis of the jaw: Diagnosis, prevention, and management. Annu Rev Med2009; 60: 85–96.
89.
AllenMRBurrDB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg2008; 66: 987–994.
90.
BurrDBAllenMR. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res2009; 12: 221–228.
91.
ShimizuHNakagamiHMoritaS. New treatment of periodontal diseases by using NF-kappaB decoy oligodeoxynucleotides via prevention of bone resorption and promotion of wound healing. Antioxid Redox Signal2009; 11: 2065–2075.
